Fundz

Pureims Secures New Investment Round To Develop Lead Inhalation Product And Facilitate Partnering Activities

PRIVATEApr 03, 2023

Round Type

Venture

DelftBiotechnologyHealth CareTherapeuticsPharmaceutical

Investors

Boost Up Foundation

Description

PureIMS, a pharmaceutical company focused on the development of dry-powder inhalation products with its proprietary CyclopsTM inhaler, today announced it has secured a new investment round. New investor Boost-UP Foundation has joined current shareholders (CardusoCapital venture capital fund, IMDS Medical Devices and LinesBridge Pharma Group) in this round to finance the company's ambitious growth strategy.

Quick answer

PureIMS raised an undisclosed amount in a funding round, dated April 3, 2023. Investors: Boost Up Foundation. PureIMS is based in Delft, South Holland, Netherlands.

How much did PureIMS raise?
PureIMS raised an undisclosed amount in a funding round on April 3, 2023.
Who invested in PureIMS?
Boost Up Foundation is named as investors in this round.
What does PureIMS do?
PureIMS is a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies, based on its proprietary dry powder inhaler Cyclops™.
Where is PureIMS based and how big is it?
PureIMS is based in Delft, South Holland, Netherlands.
Who are the decision-makers at PureIMS?
Fundz holds 1 contact at PureIMS. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Pharmaceutical around the same time

Companies in the same sectors as PureIMS that raised within 45 days of this round, from Fundz verified event records.

  • Decoy Therapeutics Inc. raised $6M on May 11, 2023.
  • Mezzion Pharma raised $40M (Funding Round) on April 25, 2023.
  • Milestone Pharmaceuticals raised $125M on March 28, 2023.
  • Azora Therapeutics, Inc. (DE) raised $62K (Pre-Seed) on February 23, 2023.
  • Pathos AI raised $20M on February 17, 2023.
  • Eikon Therapeutics raised $141M on May 18, 2023.

Who to call at PureIMS, and when

A new round usually means PureIMS is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day PureIMS raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at PureIMS, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at PureIMS. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

PureIMS

Location

Delft, South Holland, Netherlands

About

PureIMS is a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies, based on its proprietary dry powder inhaler Cyclops™. The focus is on the treatment of systemic and respiratory diseases with significant unmet medical need. The company’s leadership team consists of seasoned life sciences executives who bring long-lasting and complementary experience in leading drug development, addressing applicable scientific issues and pursuing commercial and business development & licensing opportunities. They obtained their experience in leading positions with mid-size and top-5 global Pharma companies, and with successful service providers. PureIMS’ lead candidate, Levodopa Cyclops™, is in the final development stage as rescue therapy for OFF-episodes in Parkinson’s disease. One product, Colistin Cyclops™, is already marketed and reimbursed under a named patient program for the treatment of cystic fibrosis patients. Other clinical programs – including Epinephrine Cyclops™ for (food) allergy and impending anaphylaxis – are being explored in an early clinical stage. PureIMS also supports pharma/biotech partners, applying the Cyclops™-based inhalation route for their drug of choice.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment PureIMS raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for PureIMS's next move

See what Strategic adds

PureIMS raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.